Oculis (NASDAQ:OCS) Sets New 12-Month High - Still a Buy?

Oculis Holding AG (NASDAQ:OCS - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $16.70 and last traded at $16.31, with a volume of 14447 shares trading hands. The stock had previously closed at $16.57.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Oculis in a research note on Wednesday, August 28th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $29.20.

Oculis Stock Performance

The stock has a market cap of $640.37 million, a P/E ratio of -8.88 and a beta of 0.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.27 and a quick ratio of 5.27. The company has a fifty day moving average of $12.73 and a 200 day moving average of $12.15.

Oculis (NASDAQ:OCS - Get Free Report) last announced its quarterly earnings data on Tuesday, August 27th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.13). The firm had revenue of $0.27 million during the quarter, compared to analyst estimates of $0.28 million. Oculis had a negative net margin of 7,679.05% and a negative return on equity of 61.33%. On average, equities analysts predict that Oculis Holding AG will post -2.19 earnings per share for the current fiscal year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.